Radiopharm Theranostics Advances RV01 Program with Promising Preclinical Data

Radiopharm Theranostics Limited ( (AU:RAD) ) has provided an update.

Radiopharm Theranostics announced promising preclinical data for its Lu177-B7H3-monoclonal antibody RV01, which demonstrated favorable biodistribution and high tumor uptake. This development supports plans to advance the RV01 program to a first-in-human therapeutic study for solid tumor cancers by the end of 2025. The data completes the preclinical package required for an Investigational New Drug submission, potentially enhancing the company’s position in the radiopharmaceutical industry by offering a targeted therapy with reduced toxicities.

The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.

More about Radiopharm Theranostics Limited

Radiopharm Theranostics is a clinical-stage radiotherapeutics company focused on developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in oncology. The company is listed on ASX and NASDAQ and has a pipeline that includes peptides, small molecules, and monoclonal antibodies targeting various solid tumor cancers.

Average Trading Volume: 5,961,895

Technical Sentiment Signal: Sell

Current Market Cap: A$56.02M

For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.